Epidermal growth factor receptor (EGFR) is commonly overexpressed in a number of
epithelial malignancies and is often associated with an aggressive phenotype [eg, non-small …

As the use of epidermal growth factor receptor inhibitors becomes more widespread,
increasing data are being collected regarding both efficacy and toxicity. Cutaneous toxicities …

Epidermal growth factor receptor (EGFR), a member of a family of membrane receptors with
tyrosine kinase activity, is emerging as a target candidate for anti-cancer therapy, due to its …

Gene amplification, over-expression, and mutation of growth factors, or the receptors
themselves, causes increased signaling through receptor kinases, which has been …

Squamous cell head and neck cancer (SCCHN) is the seventh most common cause of
cancer death worldwide and its incidence is rising rapidly in developing countries. Despite …

Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and
congresses. The data in the following tables has been retrieved from the Clinical Trials …

The ability of Herceptin® to prolong survival in women with HER2-overexpressing breast
tumors has proven the concept of using humanized or chimeric monoclonal antibodies …

Dermatologic events are considered the most relevant elements of the toxicity profile of
epidermal growth factor receptor (EGFR) inhibitors. However, some nondermatologic …

Objective To describe the role of tyrosine kinase (TK) and its subreceptors in the
development of cancer and the role of TK inhibitors in cancer treatment. Data Sources …

Despite improvements in the diagnosis and management of head and neck squamous cell
carcinomas, there has been minimal increase in the long-term survival in these patients over …